03:30 PM EST, 01/23/2025 (MT Newswires) -- Tiziana Life Sciences ( TLSA ) said Thursday that preclinical studies of foralumab, a nasal anti-CD3 monoclonal antibody, in traumatic spinal cord injury showed notable improvements in motor functions.

The company said it is also evaluating the drug candidate in a phase 2a study for patients with non-active secondary progressive multiple sclerosis.

Shares of Tiziana Life Sciences ( TLSA ) were up 3.2% in recent trading.

Price: 0.82, Change: +0.03, Percent Change: +3.22